Overview
Spherix’s new coverage of the irritable bowel syndrome treatment area addresses the arrival of a new mechanism of action to this more mature market. We cover how an innovative small molecule treatment could change gastroenterologists’ and primary care physician’s attitudes and algorithms in managing these patients.
Services Available
Prepping for the pipeline
-
Irritable Bowel Syndrome (US)
Service Info
Benchmarking new brand performance
-
Isbrela (Ardelyx) in Irritable Bowel Syndrome (US)
Service Info
-
Gastroenterology Biosimilars Today and Tomorrow (US)
-
Multi Specialty Impact of COVID 19 Gastroenterology (US)
-
The Business of Gastroenterology (US)
-
Fellows and Residents (US)
Service Info